文献速递血栓与止血

蛋白酶结构域外位点调控凝血因子IX(a)的血管外结合

Protease domain exosites regulate extravascular binding of factor IX(a).
PubMed 文献 · J Thromb Haemost · 2025-08-11

研究在血友病B(酶原)和血友病A(蛋白酶)小鼠中评估人凝血因子IX(a)蛋白酶结构域外位点替换(抗凝血酶R150A、肝素K126A/K132A、FIX-Padua R170A)对清除、组织分布和活性的影响,发现蛋白酶外位点调控体内清除、分布及FIX(a)活性,人FIX(a)存在广泛的血管外组织特异性结合。

要点

  • FIX野生型血浆回收差、呈双相清除及异质性组织结合,主要分布于肝,其次血浆、肾、心、脑。
  • FIX K126A/K132A血浆回收较野生型高2.3倍且肝含量降低。
  • FIXa K126A/K132A、R150A、R170A血浆回收较野生型高2至3倍。

核心结论

  • 蛋白酶外位点调控FIX(a)的体内清除、分布和活性,人FIX(a)存在广泛的血管外组织特异性结合。

研究设计与样本

  • 在血友病B小鼠(酶原)和血友病A小鼠(蛋白酶)中评估人FIX(a)蛋白酶结构域外位点替换变体。
  • 进行了FIX(a)清除的药代动力学建模、特定组织含量测定和体内活性评估。

主要发现

  • FIX野生型血浆回收差、呈双相清除和异质性组织结合,主要见于肝,其次血浆、肾、心、脑。
  • 等摩尔FIX变体与野生型相似,唯FIX K126A/K132A血浆回收高2.3倍且肝含量降低。
  • FIXa野生型较酶原清除更快,但同样血浆回收差、呈双相清除和异质性组织结合。
  • FIXa-Glu-Gly-Arg-氯甲基酮加速分布相所有隔室清除,但相对FIXa延长终末相。
  • FIXa K126A/K132A、R150A、R170A血浆回收较野生型高2至3倍,FIXa K126A/K132A肝含量降低。

关键数值与推荐

  • 尽管凝血活性降低,FIX K126A/K132A和R150A在隐静脉出血和FeCl3诱导颈动脉闭塞模型中相对FIX野生型效力完好或增强。
  • FIX R170A在两个模型中效力均增强。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Factor (F)IX is unique among the vitamin K-dependent coagulation factors in that a substantial portion is bound to extravascular sites. OBJECTIVES: Determine the impact of exosites in the human FIX protease domain on clearance, tissue distribution, and activity in hemophilic mice. METHODS: Human FIX(a) variants with protease domain substitutions in the antithrombin (R150A), heparin (K126A/K132A), and FIX-Padua (R170A) exosites were evaluated in hemophilia B (zymogen) and A (protease) mice. Pharmacokinetic modeling of FIX(a) clearance, select tissue content, and in vivo activity were determined. RESULTS: FIX wild-type (WT) demonstrated poor plasma recovery, biphasic clearance, and heterogeneous tissue binding. FIX WT was predominantly found in liver, followed by plasma, kidney, heart, and brain. Equimolar FIX variants were similar except for FIX K126A/K132A, which demonstrated 2.3-fold higher plasma recovery and reduced liver content. FIXa WT was cleared more rapidly than zymogen, but also had poor recovery, biphasic clearance, and heterogeneous tissue binding. FIXa-Glu-Gly-Arg-chloromethyl ketone accelerated clearance from all compartments in the distribution phase but prolonged the terminal phase relative to FIXa. FIXa K126A/K132A, R150A, and R170A demonstrated 2- to 3-fold higher plasma recovery than WT, with reduced liver content for FIXa K126A/K132A. Despite reduced coagulant activity, FIX K126A/K132A and R150A demonstrated intact or enhanced potency relative to FIX WT in the saphenous vein bleeding and FeCl3-induced carotid artery occlusion models, while FIX R170A had enhanced potency in both models. CONCLUSION: Protease exosites regulate in vivo clearance, distribution, and FIX(a) activity. Human FIX(a) demonstrates extensive tissue-specific binding to extravascular sites.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Westmark PR, Annis DS, Torres B, et al. Protease domain exosites regulate extravascular binding of factor IX(a). J Thromb Haemost. 2025. PMID: 40803571. doi:10.1016/j.jtha.2025.07.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。